HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy. - Wikidata - awgldk - TriplyDB

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.

http://www.wikidata.org/entity/Q37409772

about

Tenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now.Seminal HIV-1 RNA Detection in Heterosexual African Men Initiating Antiretroviral Therapy.Counseling Framework for HIV-Serodiscordant Couples on the Integrated Use of Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention.Consensus statement: Supporting Safer Conception and Pregnancy For Men And Women Living with and Affected by HIV.Antiretroviral Therapy Initiation Is Not Associated With Risky Sexual Behavior Among Heterosexual Human Immunodeficiency Virus-Infected Persons in Serodiscordant Partnerships.Achieving pregnancy safely for HIV-serodiscordant couples: a social ecological approach Patterns of residual HIV-1 RNA shedding in the seminal plasma of patients on effective antiretroviral therapy.Virologic outcomes in early antiretroviral treatment: HPTN 052.HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial.Semen as the Way Forward to Understand HIV-1 Transmission.Scale-up of Kenya's national HIV viral load program: Findings and lessons learned.The microbiome and HIV persistence: implications for viral remission and cure.Maximizing the Benefits of HIV Preexposure Prophylaxis.

P2860

Q36146022-7225878A-5F18-417B-B76B-289D2DC0D055 Q37033062-2149CBBE-0F93-4A21-A437-69AF770A6517 Q37488475-BC6C0807-331B-4C8D-BCED-9658507FD7EA Q38787423-2747F5CF-809A-4C4F-A08B-31816ECF3DBD Q38852013-8C1F9BD8-CC71-4A58-8926-D0EA352B2A7D Q39210468-0386BD48-7A03-44E5-B8A1-F32755866830 Q40042087-C550D35D-CD81-4BC4-BE75-C1A5A2206025 Q40254515-3A8BA016-5EEB-49CD-B125-83607D02D1D5 Q40353844-58C0FE4C-4E27-4CAE-8244-0E6CB4ACA4FB Q40572857-6260523F-DA55-45A1-8D14-2B1B20A8DAA3 Q44238958-5A787B27-73AF-41FE-B5E7-FB2D4B9241AF Q47555214-9D66195D-939E-4FBC-B7AA-ECF0F24441CB Q47580980-34EB90E6-2450-4A93-99C0-EB8BF746C222 Q52566642-DA907C4E-BD18-4E55-8D1B-A68087750543

P2860

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.

http://www.wikidata.org/entity/Q37409772

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.

@en

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.

@nl

type

label

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.

@en

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.

@nl

prefLabel

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.

@en

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.

@nl

P1433

Q37409772-662C4425-69F3-45E2-8D1E-9F86A16B817E

P1476

Q37409772-A5A1925A-A857-4B04-88D8-7DE16B89D20F

P2093

Q37409772-419E3D06-61E7-4C1B-A888-7D439D71E15D

Q37409772-53EBF420-FFFF-4C48-A612-0D7460864176

Q37409772-6B6861AB-AB62-4D8E-A7F3-89FE2A994898

Q37409772-74AA4628-97B6-4753-A7B4-691419AB8D7D

Q37409772-84B7F01D-9B98-4C0C-B0C7-7ED2897BBE32

Q37409772-B839FBF9-4A04-4F2A-BF10-A56D1F69EA5E

Q37409772-CE681287-EA6D-466C-8ADC-A229D1A5DD70

Q37409772-D71DEC1D-4740-48C4-8FE4-B454C165098A

Q37409772-D7F3363D-923C-49E8-9C95-4253959F8949

Q37409772-FB9A99DA-3A37-4737-9760-575428148DAD

P2860

Q37409772-109C63E2-0B21-450B-BF08-713A934461B4

Q37409772-1D681C91-732C-4416-86F9-E9E1EDF2EBDC

Q37409772-26BA4F93-2DCC-4E9B-AB29-DCDE2BCE10A4

Q37409772-3706FFF7-7342-4850-A60B-64383527D92B

Q37409772-4105A49A-1C9D-42F0-954C-6EF82E259185

Q37409772-52D67B7E-E3A1-42D0-96DC-09DFB9280FD2

Q37409772-54E5D934-703C-4999-AFB5-BA9C7FEE4B65

Q37409772-6CCDD8F2-D365-41C1-8593-9B3A0F1CAFFE

Q37409772-72B55D6B-0CC0-4017-B799-725D114529A8

Q37409772-78ECF3B4-1E42-4A8E-9B0A-4431CD6EA174

P304

Q37409772-13C80CFB-2B80-414A-920F-D692856BCCE9

P31

Q37409772-AD3F3302-F57E-4884-AF8D-D8E4A6FE4B55

P356

Q37409772-BE7CC4BD-E532-4219-AD03-12887546DFCB

P407

Q37409772-9921D9CE-6FFA-498D-80B0-969F38DDFAAC

P433

Q37409772-7B1CF898-53F9-434E-A218-19EFF3605224

P478

Q37409772-C3052100-B486-48ED-9332-2D0171A879F6

P50

Q37409772-8BE13755-CAFF-4A54-9C1C-B6B524B83585

Q37409772-C2C27A9C-A431-440D-BA26-1EE14F281746

P577

Q37409772-22AACF9E-4194-4049-B249-E6A0F179BBD3

P698

Q37409772-7BFB070D-E940-4D59-BED6-DBAC2A8DD4FA

P921

Q37409772-535A0BBF-0A00-4D83-AE93-87D89EC0098B

Q37409772-9806E05D-C37E-437C-BAF1-44D4DB3B07C0

Q37409772-CD82A38F-5AE9-4363-9549-341732740FB1

P932

Q37409772-7A797FC6-874E-4308-9A2E-D32F0A4D87BC

P356

QAI.0000000000001019

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.

@en

P2093

Allan Ronald

http://www.w3.org/2001/XMLSchema#string

Andrew Mujugira

http://www.w3.org/2001/XMLSchema#string

Edwin Were

http://www.w3.org/2001/XMLSchema#string

James D Campbell

http://www.w3.org/2001/XMLSchema#string

James Kiarie

http://www.w3.org/2001/XMLSchema#string

Jared M Baeten

http://www.w3.org/2001/XMLSchema#string

Nelly Mugo

http://www.w3.org/2001/XMLSchema#string

Partners PrEP Study Team

http://www.w3.org/2001/XMLSchema#string

Patrick Ndase

http://www.w3.org/2001/XMLSchema#string

Robert W Coombs

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of HIV-1 infection with early antiretroviral therapy

New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond

Detection and characterization of hepatitis C virus RNA in seminal plasma and spermatozoon fractions of semen from patients attempting medically assisted conception

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

Decay characteristics of HIV-1-infected compartments during combination therapy

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.

Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study.

Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis

P304

579-584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000001019

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth Bukusi

P577

2016-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27070123

http://www.w3.org/2001/XMLSchema#string

P921

HIV transmission

antiretroviral drug

P932

5106226

http://www.w3.org/2001/XMLSchema#string